The Medicines Company Reports Fourth-Quarter And Full-Year 2016 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced its financial results for the fourth-quarter and full-year ended December 31, 2016.
“Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We announced positive top-line results from the ORION-1 Phase II study of inclisiran, which continued to demonstrate compelling safety and efficacy data, reinforcing our belief in its highly-differentiated and competitive profile and providing a strong basis for advancing inclisiran into Phase III. We look forward to presenting full safety and efficacy data from the ORION-1 study, with six- to nine-month follow-up for all study patients, in the Late-Breaking Clinical Trials session at the American College of Cardiology’s 66th Annual Scientific Session.”
“Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We announced positive top-line results from the ORION-1 Phase II study of inclisiran, which continued to demonstrate compelling safety and efficacy data, reinforcing our belief in its highly-differentiated and competitive profile and providing a strong basis for advancing inclisiran into Phase III. We look forward to presenting full safety and efficacy data from the ORION-1 study, with six- to nine-month follow-up for all study patients, in the Late-Breaking Clinical Trials session at the American College of Cardiology’s 66th Annual Scientific Session.”